Unknown

Dataset Information

0

Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.


ABSTRACT: Triple-negative breast cancer (TNBC) remains an aggressive disease without effective targeted therapies. In this study, we addressed this challenge by testing 128 FDA-approved or investigational drugs as either single agents or in 768 pairwise drug combinations in TNBC cell lines to identify synergistic combinations tractable to clinical translation. Medium-throughput results were scrutinized and extensively analyzed for sensitivity patterns, synergy, anticancer activity, and were validated in low-throughput experiments. Principal component analysis revealed that a fraction of all upregulated or downregulated genes of a particular targeted pathway could partly explain cell sensitivity toward agents targeting that pathway. Combination therapies deemed immediately tractable to translation included ABT-263/crizotinib, ABT-263/paclitaxel, paclitaxel/JQ1, ABT-263/XL-184, and paclitaxel/nutlin-3, all of which exhibited synergistic antiproliferative and apoptotic activity in multiple TNBC backgrounds. Mechanistic investigations of the ABT-263/crizotinib combination offering a potentially rapid path to clinic demonstrated RTK blockade, inhibition of mitogenic signaling, and proapoptotic signal induction in basal and mesenchymal stem-like TNBC. Our findings provide preclinical proof of concept for several combination treatments of TNBC, which offer near-term prospects for clinical translation. Cancer Res; 77(2); 566-78. ©2016 AACR.

SUBMITTER: Wali VB 

PROVIDER: S-EPMC5582957 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.

Wali Vikram B VB   Langdon Casey G CG   Held Matthew A MA   Platt James T JT   Patwardhan Gauri A GA   Safonov Anton A   Aktas Bilge B   Pusztai Lajos L   Stern David F DF   Hatzis Christos C  

Cancer research 20161121 2


Triple-negative breast cancer (TNBC) remains an aggressive disease without effective targeted therapies. In this study, we addressed this challenge by testing 128 FDA-approved or investigational drugs as either single agents or in 768 pairwise drug combinations in TNBC cell lines to identify synergistic combinations tractable to clinical translation. Medium-throughput results were scrutinized and extensively analyzed for sensitivity patterns, synergy, anticancer activity, and were validated in l  ...[more]

Similar Datasets

| S-EPMC4569194 | biostudies-literature
| S-EPMC4303459 | biostudies-other
| S-EPMC10452226 | biostudies-literature
| S-EPMC5607299 | biostudies-literature
| S-EPMC5995333 | biostudies-literature
| S-EPMC8635244 | biostudies-literature
2023-08-15 | GSE229428 | GEO
| S-EPMC4102798 | biostudies-other
| S-EPMC8096163 | biostudies-literature
| S-EPMC5265847 | biostudies-other